Vireo Growth (VREOF) Shares Outstanding (Weighted Average) (2020 - 2026)
Vireo Growth's (VREOF) quarterly Shares Outstanding (Weighted Average) came in at $1.1 billion in Q1 2026, up 6868.88% year-on-year from $15.5 million in Q1 2025, and up 35468.65% quarter-over-quarter from $3.0 million in Q4 2025.
Vireo Growth (VREOF) Shares Outstanding (Weighted Average) (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Shares Outstanding (Weighted Average) across 7 years of filings, most recently posting $1.1 billion for Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $1.1 billion, up 6868.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 6868.88% YoY), and the FY2025 annual result was $3.0 million, down 98.32% from the prior year.
- Shares Outstanding (Weighted Average) came in at $1.1 billion for Q1 2026 at Vireo Growth, up from $3.0 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $1.1 billion in Q1 2026 to a low of $3.0 million in Q3 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $128.1 million (2022), against an average of $185.5 million.
- Across the five-year window, Shares Outstanding (Weighted Average) jumped 943074.03% in 2022 and slumped 97.63% in 2023, its largest moves.
- Vireo Growth's Shares Outstanding (Weighted Average) stood at $3.0 million in 2022, then soared by 439.89% to $16.4 million in 2023, then slumped by 81.48% to $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025, then jumped by 35468.65% to $1.1 billion in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $1.1 billion (Q1 2026), $3.0 million (Q4 2025), and $627.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.16 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 422.10 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 43.50 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 5.02 Bn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 100.50 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 497.70 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 166.20 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 228.36 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 64.74 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 1.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Bn |
| Dec 31, 2025 | 3.04 Mn |
| Sep 30, 2025 | 627.65 Mn |
| Jun 30, 2025 | 559.10 Mn |
| Mar 31, 2025 | 15.50 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 162.84 Mn |
| Jun 30, 2024 | 16.20 Mn |
| Mar 31, 2024 | 143.13 Mn |
| Dec 31, 2023 | 16.40 Mn |
| Sep 30, 2023 | 132.58 Mn |
| Jun 30, 2023 | 3.04 Mn |
| Mar 31, 2023 | 128.13 Mn |
| Dec 31, 2022 | 3.04 Mn |
| Sep 30, 2022 | 3.04 Mn |
| Jun 30, 2022 | 128.11 Mn |
| Mar 31, 2022 | 128.11 Mn |
| Dec 31, 2021 | 13,583.00 |
| Sep 30, 2021 | 3.04 Mn |
| Jun 30, 2021 | 13,583.00 |